Novel Potential Therapeutic Targets in Autosomal Dominant Polycystic Kidney Disease from the Perspective of Cell Polarity and Fibrosis

被引:2
|
作者
Ahn, Yejin [1 ]
Park, Jong Hoon [1 ,2 ]
机构
[1] Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea
[2] Sookmyung Womens Univ, Res Inst Womens Hlth, Seoul 04310, South Korea
关键词
ADPKD; Kidney; Cell polarity; Fibrosis; Therapeutic target; DEACETYLASE; 6; ACTIVITY; PROTEIN-KINASE AMPK; E-CADHERIN; RENAL CYSTOGENESIS; CLINICAL-TRIAL; MTOR PATHWAY; CYST GROWTH; MOUSE MODEL; IN-VITRO; INHIBITION;
D O I
10.4062/biomolther.2023.207
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Autosomal dominant polycystic kidney disease (ADPKD), a congenital genetic disorder, is a notable contributor to the prevalence of chronic kidney disease worldwide. Despite the absence of a complete cure, ongoing research aims for early diagnosis and treatment. Although agents such as tolvaptan and mTOR inhibitors have been utilized, their effectiveness in managing the disease during its initial phase has certain limitations. This review aimed to explore new targets for the early diagnosis and treatment of ADPKD, considering ongoing developments. We particularly focus on cell polarity, which is a key factor that influences the process and pace of cyst formation. In addition, we aimed to identify agents or treatments that can prevent or impede the progression of renal fibrosis, ultimately slowing its trajectory toward end -stage renal disease. Recent advances in slowing ADPKD progression have been examined, and potential therapeutic approaches targeting multiple pathways have been introduced. This comprehensive review discusses innovative strategies to address the challenges of ADPKD and provides valuable insights into potential avenues for its prevention and treatment.
引用
收藏
页码:291 / 300
页数:10
相关论文
共 50 条
  • [1] Novel targets for the treatment of autosomal dominant polycystic kidney disease
    Belibi, Franck A.
    Edelstein, Charles L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (03) : 315 - 328
  • [2] Novel therapeutic approaches to autosomal dominant polycystic kidney disease
    Lariviere, Wells B.
    Irazabal, Maria V.
    Torres, Vicente E.
    TRANSLATIONAL RESEARCH, 2015, 165 (04) : 488 - 498
  • [3] Autosomal dominant polycystic kidney disease: Novel therapeutic options
    Serra A.L.
    Poster D.
    Wüthrich R.P.
    Der Nephrologe, 2010, 5 (5): : 404 - 411
  • [4] Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential
    Nowak, Kristen L.
    Hopp, Katharina
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (04): : 577 - 584
  • [5] Autosomal dominant polycystic kidney disease: A genetic perspective
    Harris, PC
    NEPHROLOGY, 1997, 3 (05) : 387 - 395
  • [6] Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions
    Malekshahabi, Talieh
    Rad, Niloofar Khoshdel
    Serra, Andreas L.
    Moghadasali, Reza
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (08) : 12451 - 12470
  • [7] Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Norman, Jill
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2011, 1812 (10): : 1327 - 1336
  • [8] Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis
    Xu, Nancy
    Glockner, James F.
    Rossetti, Sandro
    Babovic-Vuksanovic, Dusica
    Harris, Peter C.
    Torres, Vicente E.
    JOURNAL OF NEPHROLOGY, 2006, 19 (04) : 529 - 534
  • [9] The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease
    Fragiadaki, Maria
    Macleod, Fiona M.
    Ong, Albert C. M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) : 1 - 15
  • [10] Novel Treatments of Autosomal Dominant Polycystic Kidney Disease
    Mahnensmith, Rex L.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (05): : 831 - 836